141 related articles for article (PubMed ID: 23820451)
1. FDA advisers favor easing rosiglitazone restrictions.
Traynor K
Am J Health Syst Pharm; 2013 Jul; 70(14):1184-5. PubMed ID: 23820451
[No Abstract] [Full Text] [Related]
2. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
3. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
4. [What about the controversy regarding rosiglitazone].
Scheen AJ; De Flines J; Paquot N
Rev Med Liege; 2007 Sep; 62(9):560-5. PubMed ID: 17966792
[TBL] [Abstract][Full Text] [Related]
5. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
6. Rosiglitazone and the FDA.
Krall RL
N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
[No Abstract] [Full Text] [Related]
7. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
8. FDA advisers recommend new controls on rosiglitazone use.
Traynor K
Am J Health Syst Pharm; 2010 Aug; 67(16):1306-8. PubMed ID: 20689113
[No Abstract] [Full Text] [Related]
9. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
10. Avandia outcome may signal change in epidemiologists' sway.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
[No Abstract] [Full Text] [Related]
11. The long Avandia endgame.
Mullard A
Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
[No Abstract] [Full Text] [Related]
12. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
13. FDA panel advises easing restrictions on rosiglitazone.
Tucker ME
BMJ; 2013 Jun; 346():f3769. PubMed ID: 23752055
[No Abstract] [Full Text] [Related]
14. The truth about rosiglitazone (avandia).
Ledbetter C; Laustsen G
Nurse Pract; 2008 Jun; 33(6):10-1. PubMed ID: 18528195
[No Abstract] [Full Text] [Related]
15. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
16. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
Nathan DM; Berkwits M
Ann Intern Med; 2007 Mar; 146(6):461-3. PubMed ID: 17371892
[No Abstract] [Full Text] [Related]
17. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
18. Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas PC; Sarafidis PA; Lasaridis AN
J Cardiometab Syndr; 2007; 2(4):295-6. PubMed ID: 18059214
[No Abstract] [Full Text] [Related]
19. FDA on rosiglitazone. More on advisory committee decision.
Graham DJ; Gelperin K
BMJ; 2010 Sep; 341():c4868. PubMed ID: 20823021
[No Abstract] [Full Text] [Related]
20. FDA eases restrictions on the glucose-lowering drug rosiglitazone.
Mitka M
JAMA; 2013 Dec; 310(24):2604. PubMed ID: 24368444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
